Author

T. J. Maimone

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 4 Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 6 Approach:experimental assay· 6 Organism:human· 6 Assay:proteomics· 5

Frequent Co-Authors

D. K. Nomura· 6 shared J. A. Tallarico· 4 shared J. M. McKenna· 4 shared M. Schirle· 4 shared X. Hu· 3 shared B. Tong· 2 shared J. A. Olzmann· 2 shared J. N. Spradlin· 2 shared

Activity by Year

2019-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersBiochemistry

D. K. Nomura

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Ophiobolin A Covalently Targets Complex IV Leading to Mitochondrial Metabolic Collapse in Cancer Cells

F. A. Gowans, D. Q. Thach, Y. Wang, B. E. A. Poblano, D. Dovala, J. A. Tallarico, J. M. McKenna, M. Schirle, T. J. Maimone, D. K. Nomura

This study identifies Ophiobolin A's covalent targets in complex IV of mitochondria, revealing a mechanism of metabolic collapse and cell death in cancer cells.

bioRxiv · Mar 9, 2023Biochemistry

Chemoproteomic Profiling Reveals that Anti-Cancer Natural Product Dankastatin B Covalently Targets Mitochondrial VDAC3

B. P. Belcher, P. A. Machicao, B. Tong, E. Ho, J. Friedli, B. So, H. Bui, Y. Isobe, T. J. Maimone, D. K. Nomura

This study identifies dankastatin B as a covalent inhibitor of VDAC3 in breast cancer cells, revealing its mechanism of action through chemoproteomic profiling.

bioRxiv · Feb 11, 2023 · PreprintBiochemistry

A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL

B. Tong, J. N. Spradlin, L. F. T. Novaes, E. Zhang, X. Hu, M. Moeller, S. M. Brittain, L. M. McGregor, J. M. McKenna, J. A. Tallarico, M. Schirle, T. J. Maimone, D. K. Nomura

This paper develops a PROTAC molecule, BT1, that selectively degrades BCR-ABL over c-ABL in leukemia cells using nimbolide as an E3 ligase recruiter, showing additional anti-proliferative effects.

bioRxiv · Apr 2, 2020Biochemistry

Manumycin Polyketides Act as Molecular Glues Between UBR7 and P53 to Impair Breast Cancer Pathogenicity

Y. Isobe, M. Okumura, R. White, L. M. McGregor, J. M. McKenna, J. A. Tallarico, M. Schirle, T. J. Maimone, D. K. Nomura

The paper identifies manumycin polyketides as molecular glues that bind UBR7 and P53, impairing breast cancer pathogenicity through p53 activation and cell death.

bioRxiv · Oct 22, 2019 · PreprintBiochemistry

Harnessing the Anti-Cancer Natural Product Nimbolide for Targeted Protein Degradation

J. N. Spradlin, X. Hu, C. C. Ward, S. M. Brittain, M. D. Jones, L. Ou, M. To, A. Proudfoot, E. Ornleas, M. Woldegiorgis, J. A. Olzmann, D. E. Bussiere, J. R. Thomas, J. A. Tallarico, J. M. McKenna, , D. K. Nomura

This study identifies nimbolide's mechanism of action by showing it targets RNF114, leading to stabilization of p21 and inhibition of breast cancer cell proliferation.

bioRxiv · Apr 9, 2019Cancer Biology

Parthenolide Covalently Targets and Inhibits Focal Adhesion Kinase in Breast Cancer Cells

C. A. Berdan, R. Ho, H. S. Lehtola, M. To, X. Hu, T. R. Huffman, Y. Petri, C. R. Altobelli, S. G. Demeulenaere, J. A. Olzmann, T. J. Maimone, D. K. Nomura

This study identifies parthenolide's covalent targeting of FAK1 in breast cancer cells, showing inhibition of FAK1-dependent pathways and cancer cell proliferation.

bioRxiv · Feb 15, 2019Cancer Biology